Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sotac PharmaceuticalsNSE:SOTAC 50 Cash Ratio is 0.01 as of Sep. 2024, which is 67% below its 10-year median of 0.03. GuruFocus rates NSE:SOTAC with a GF Score™ of 50/100 and a GF Value™ of ₹136.86 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 965 Drug Manufacturers companies, Sotac Pharmaceuticals ranks worse than 94.92% on this metric.
Sotac Pharmaceuticals has a Cash Ratio of 0.01. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Sotac Pharmaceuticals's Cash Ratio or its related term are showing as below:
NSE:SOTAC'
s Cash Ratio Range Over the Past 10 Years
Min: 0.02 Med: 0.03 Max: 0.21
Current: 0.02
During the past 7 years, Sotac Pharmaceuticals's highest Cash Ratio was 0.21. The lowest was 0.02. And the median was 0.03.
NSE:SOTAC's Cash Ratio is ranked worse than 94.92% of 965
companies
in the Drug Manufacturers industry
Industry Median: 0.57
vs NSE:SOTAC: 0.02
Sotac Pharmaceuticals (NSE:SOTAC) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sotac Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sotac Pharmaceuticals Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sotac Pharmaceuticals's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Sotac Pharmaceuticals's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sotac Pharmaceuticals (NSE:SOTAC) has a Cash Ratio of 0.01 as of Sep. 2024. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Sotac Pharmaceuticals and its competitors. This is 67% below median its historical median of 0.03. Over the past decade, Sotac Pharmaceuticals' Cash Ratio has ranged from 0.02 to 0.21. According to the industry distribution chart, Sotac Pharmaceuticals ranks #916 out of 965 companies in the Drug Manufacturers industry, placing it in the top 94.9%.
Is Sotac Pharmaceuticals' Cash Ratio too high?
Sotac Pharmaceuticals' current Cash Ratio of 0.01 is 67% below median its 10-year median of 0.03. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.21. The Drug Manufacturers industry median Cash Ratio is 0.57. Sotac Pharmaceuticals' value of 0.01 is 98.2% below this industry median. Based on the distribution chart, Sotac Pharmaceuticals ranks #916 out of 965 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sotac Pharmaceuticals has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sotac Pharmaceuticals' Cash Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sotac Pharmaceuticals ranks #916 out of 965 companies for Cash Ratio. This places Sotac Pharmaceuticals in the lower half of its industry. The industry median Cash Ratio is 0.57. Sotac Pharmaceuticals' value of 0.01 is 98.2% below this benchmark. Historically, Sotac Pharmaceuticals' own Cash Ratio has ranged from 0.02 to 0.21 over the past decade. While the company's 10-year median is 0.03 vs. the industry median of 0.57, Sotac Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.57, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sotac Pharmaceuticals's current Cash Ratio of 0.01 is 98.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Sotac Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sotac Pharmaceuticals's current Cash Ratio is 0.01, which is 67% below median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotac Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Sotac Pharmaceuticals (NSE:SOTAC) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹136.86, compared to a current price of ₹90.05 — trading 34.2% below its estimated fair value. The current Cash Ratio is 0.01, which is 67% below median its 10-year median of 0.03 and 98.2% below the Drug Manufacturers industry median of 0.57. Sotac Pharmaceuticals' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Sotac Pharmaceuticals (NSE:SOTAC), the current Cash Ratio is 0.01 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sotac Pharmaceuticals (NSE:SOTAC) Overvalued in 2026?
Based on GuruFocus' analysis, Sotac Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹90.05 is trading 34.2% below its estimated GF Value™ of ₹136.86.
GuruFocus considers Sotac Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:SOTAC:
Cash Ratio: 0.01 (67% below median its 10-year median of 0.03)
GF Value™: ₹136.86 vs. price of ₹90.05 (34.2% below fair value)
Industry Position: 98.2% below the Drug Manufacturers median (#916 of 965)
No single metric tells the full story. See the NSE:SOTAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sotac Pharmaceuticals Ltd operates chiefly in pharmaceutical manufacturing, serving a broad range of therapeutic segments including anti-diabetic, anti-psychotic, vitamins and minerals, anti-cold, anti-allergic, derma products, antacids, anti-ulcerants, cardiac, analgesic, anti-bacterial, anti-fungal, and more. The company manufactures tablets, capsules, syrups, and external preparations under contract manufacturing and loan licensing agreements, for domestic and international markets. Its clients include notable pharmaceutical marketers such as Cadila Pharma and Viatris. Revenue is distributed between domestic pharmaceutical product sales and international exports, supporting scalable growth across geographies.
50GF Score
Get the complete analysis for NSE:SOTAC
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SOTAC has been successfully added to your 
